Cited by 569Sarcoidosis and Beryllium Toxicity ResearchHistiocytic Disorders and TreatmentsCardiac tumors and thrombi

Cardiac Sarcoidosis

Open access
Birnie, David H., Nery, Pablo B., Ha, Andrew C., Beanlands, Rob S.B.·2016·Journal of the American College of Cardiology

Abstract

Clinically manifest cardiac involvement occurs in perhaps 5% of patients with sarcoidosis. The 3 principal manifestations of cardiac sarcoidosis (CS) are conduction abnormalities, ventricular arrhythmias, and heart failure. An estimated 20% to 25% of patients with pulmonary/systemic sarcoidosis have asymptomatic cardiac involvement (clinically silent disease). In 2014, the first international guideline for the diagnosis and management of CS was published. In patients with clinically manifest CS, the extent of left ventricular dysfunction seems to be the most important predictor of prognosis. There is controversy in published reports as to the outcome of patients with clinically silent CS. Despite a paucity of data, immunosuppression therapy (primarily with corticosteroids) has been advocated for the treatment of clinically manifest CS. Device therapy, primarily with implantable cardioverter-defibrillators, is often recommended for patients with clinically manifest disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2016.03.605

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 10

  1. [3]3. Hillerdal G, Nöu E, Osterman K, et al. Sarcoid- osis: epidemiology and prognosis. A 15-year Eu- ropean study. Am Rev Respir Dis 1984;130:29-32.
  2. [4]4. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet 2014;383:1155-67.
  3. [5]5. Rybicki BA, Iannuzzi MC, Frederick MM, et al., for the ACCESS Research Group. Familial aggre- gation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001;164:2085-91.
  4. [11]11. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015;131:624-32.
  5. [36]36. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153-65.
  6. [53]53. Liang JJ, Hebl VB, DeSimone CV, et al. Elec- trogram guidance: a method to increase the pre- cision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. J Am Coll Cardiol HF 2014;2:466-73.
  7. [55]55. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Dis- ord 2007;27:89-102.
  8. [56]56. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr., for the ACCESS Research Group. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:75-86.
  9. [58]58. Sadek MM, Yung D, Birnie DH, et al. Cortico- steroid therapy for cardiac sarcoidosis: a system- atic review. Can J Cardiol 2013;29:1034-41.
  10. [72]72. Dhôte R, Vignaux O, Blanche P, et al. [Value of MRI for the diagnosis of cardiac involvement in sarcoidosis]. Rev Med Interne 2003;24:151-7.

Cited by

Sorted by citations

Authors
Birnie, D. H., Nery, P. B., Ha, A. C., & Beanlands, R. S. B.
Affiliations
  • Ottawa Heart Institute (CA)
  • University Health Network (CA)
Corresponding author
Birnie, David H.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2016-07
Volume
68
Issue
4
Pages
411-421
ISSN
0735-1097 (ISSN-L)
OpenAlex
W4205862288
Cited by
569
References
71
Citations by year
2026: 37 · 2025: 67 · 2024: 69 · 2023: 69 · 2022: 76 · 2021: 58 · 2020: 67 · 2019: 54 · 2018: 37 · 2017: 33 · 2016: 1
FWCI
4.90
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Sarcoidosis and Beryllium Toxicity Research
  • Health Sciences › Medicine › Physiology › Histiocytic Disorders and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
Keywords
cardiac sarcoidosis, conduction abnormalities, ventricular arrhythmias, heart failure, left ventricular dysfunction, prognosis, corticosteroid immunosuppression, implantable cardioverter-defibrillator, device therapy
MeSH terms
Diagnostic Imaging, Electrocardiography, Humans, Cardiomyopathies, Prognosis, Sarcoidosis, Magnetic Resonance Imaging, Cine, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review